Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
17β-estradiol + micronized progesterone
- Development stage
- Phase 4
- Lead developer
- TherapeuticsMD
- Modality
- Small Molecules
- Administration
- Transdermal, Oral
01
Overview
This hormone replacement therapy regimen consists of a 100-μg 17β-estradiol transdermal patch administered continuously, paired with 200 mg of cyclic oral micronized progesterone for 12 days each month. Developed and studied by researchers at Massachusetts General Hospital, this physiologic replacement strategy is designed to treat bone loss in adolescent and young adult female athletes with hypothalamic amenorrhea or oligoamenorrhea. Unlike oral contraceptives, which can suppress IGF-1 levels and potentially hinder bone accrual, this transdermal delivery bypasses first-pass hepatic metabolism, maintaining IGF-1 levels and more effectively improving bone mineral density at the spine and hip. The regimen aims to optimize peak bone mass during the critical window of adolescent development.
- Other names
- Physiologic estrogen replacementTransdermal estradiol and cyclic progesterone
02
Targets
ER (Estrogen receptor)PR (Progesterone receptor)PGRMC1PGRMC2 (Progesterone receptor membrane component 2)mPRα (Membrane progesterone receptor alpha)mPRβ (Membrane progesterone receptor beta)
Beyond the preview
Go deeper on 17β-estradiol + micronized progesterone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 17β-estradiol + micronized progesterone.